Cargando…

Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

BACKGROUND: Tigecycline is a vital antibiotic treatment option for infections caused by multiresistant bacteria in the intensive care unit (ICU). Acute kidney injury (AKI) is a common complication in the ICU requiring continuous renal replacement therapy (CRRT), but pharmacokinetic data for tigecycl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broeker, A., Wicha, S. G., Dorn, C., Kratzer, A., Schleibinger, M., Kees, F., Heininger, A., Kees, M. G., Häberle, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296114/ https://www.ncbi.nlm.nih.gov/pubmed/30558639 http://dx.doi.org/10.1186/s13054-018-2278-4

Ejemplares similares

Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients
por: Amann, Lisa F., et al.
Publicado: (2022)

Population pharmacokinetics of tigecycline in critically ill patients
por: Luo, Xiangru, et al.
Publicado: (2023)

Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda
por: Cutuli, Salvatore Lucio, et al.
Publicado: (2020)

An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy
por: Broeker, Astrid, et al.
Publicado: (2020)

Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis
por: Dorn, Christoph, et al.
Publicado: (2022)

Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
por: Grensemann, Jörn, et al.
Publicado: (2021)

The pharmacokinetics of tigecycline in critically ill adult patients undergoing CVVHD
por: Rypulak, E, et al.
Publicado: (2015)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)
por: Alraish, Rawan, et al.
Publicado: (2020)

Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy
por: Kunka, Megan E., et al.
Publicado: (2015)

Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents
por: Amann, Lisa F., et al.
Publicado: (2020)

Continuous renal replacement therapy in critically ill neonates
por: Rödi, S, et al.
Publicado: (1998)

Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
por: De Pascale, Gennaro, et al.
Publicado: (2020)

The blind spot in high-dose tigecycline pharmacokinetics in critically ill patients: membrane adsorption during continuous extracorporeal treatment
por: Honore, Patrick M, et al.
Publicado: (2015)

No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure
por: Honore, Patrick M., et al.
Publicado: (2020)

Continuous Renal Replacement Therapy in Critically Ill Children
por: Demirkol, Demet
Publicado: (2022)

Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: He, Sha, et al.
Publicado: (2022)

1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy
por: Kline, Ellen G, et al.
Publicado: (2020)

Renal replacement therapy for critically ill patients: an intermittent continuity
por: Ricci, Zaccaria, et al.
Publicado: (2014)

Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient
por: González-Fernández, M., et al.
Publicado: (2023)

Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
por: Tikiso, Tjokosela, et al.
Publicado: (2023)

Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?
por: Roberts, Jason A, et al.
Publicado: (2014)

Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
por: Kiser, Tyree H, et al.
Publicado: (2015)

Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial
por: Onichimowski, Dariusz, et al.
Publicado: (2020)

Linezolid pharmacokinetics in critically ill patients with renal replacement therapy: comparison of equi-dose of continuous veno-venous haemofiltration with continuous veno-venous haemodiafiltration
por: Roger, C, et al.
Publicado: (2015)

Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study
por: Meenks, Sjoerd D., et al.
Publicado: (2023)

Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?
por: Omrani, Ali S., et al.
Publicado: (2015)

Clearance of meropenem during continuous renal replacement therapy in critically ill patients
por: Thalhammer, F, et al.
Publicado: (1999)

Hemodynamic impact of the connection to continuous renal replacement therapy in critically ill children
por: Fernández, Sarah, et al.
Publicado: (2018)

Continuous renal replacement therapy in critically ill children: single-center experience
por: ERKOL TUNCER, Hatice, et al.
Publicado: (2021)

Pharmacokinetics of linezolid in critically ill patients undergoing continuous venovenous hemofiltration
por: Meyer, B, et al.
Publicado: (2004)

Pharmacokinetic/pharmacodynamic analysis of linezolid in critically ill patients with severe sepsis treated with renal replacement therapy
por: Barrasa González, H, et al.
Publicado: (2015)

Biomarker validity in the critically ill: all must face the (continuous) renal replacement challenge!
por: Honore, Patrick M., et al.
Publicado: (2015)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients
por: Roberts, Jason A., et al.
Publicado: (2016)

Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini‐review and population pharmacokinetic analysis
por: Selig, Daniel J., et al.
Publicado: (2022)

Pharmacokinetics of meropenem in intensive care patients receiving continuous renal replacement therapy
por: Giles, LJ, et al.
Publicado: (1998)

Renal replacement in critically ill patients: the age factor
por: Occhigrossi, F, et al.
Publicado: (2004)

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series
por: Mornese Pinna, Simone, et al.
Publicado: (2022)

Citrate Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients: Success and Limits
por: Mariano, Filippo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_t3n4qk9eho8qmc80iableeh9tp